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Abstract: Silver nanoparticles are increasingly finding applications in medicine; however, 
little is known about their in vivo tissue distribution. Here, we have developed a rapid 
method for radiolabeling of silver nanoparticles with iodine-125 in order to track in vivo 
tissue uptake of silver nanoparticles after systemic administration by biodistribution analysis 
and single-photon emission computerized tomography (SPECT) imaging. Poly(N-vinyl-2
-pyrrolidone)-capped silver nanoparticles with an average size of 12 nm were labeled by 
chemisorption of iodine-125 with a .80% yield of radiolabeling efficiency. Radiolabeled 
silver nanoparticles were intravenously injected in Balb/c mice, and the in vivo distribution 
pattern of these nanoparticles was evaluated by noninvasive whole-body SPECT imaging, 
which revealed uptake of the nanoparticles in the liver and spleen. Biodistribution analysis 
confirmed predominant accumulation of the silver nanoparticles in the spleen (41.5%ID/g) 
and liver (24.5%ID/g) at 24 h. Extensive uptake in the tissues of the reticuloendothelial 
system suggests that further investigation of silver nanoparticle interaction with hepatic 
and splenic tissues at the cellular level is critical for evaluation of the in vivo effects and 
potential toxicity of silver nanoparticles. This method enables rapid iodine-125 radiolabeling 
of silver nanoparticles with a specific activity sufficient for in vivo imaging and biodistribu-
tion analysis.
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Introduction
Silver nanoparticles (Ag NPs) have attracted much attention recently because of 
their broad-spectrum antimicrobial activities. Ag NPs have therefore found   extensive 
  medical applications in catheter coatings,1 wound dressings,2 and antimicrobial 
creams and lotions.3 Furthermore, because of the antibacterial effects of Ag NPs, 
these particles are currently utilized in a variety of everyday products, including 
laundry detergents, water purificants, washing machines, deodorants, floor coatings, 
wall paints, textiles, containers, shower curtains, and tabletops.4–6 Colloidal silver 
has even been promoted as an oral supplement to prevent and treat many diseases.7 
  Multiple therapeutic   applications and extensive utilization of Ag NPs in surface 
coatings inherently lead to environmental and/or internal exposure of the human 
body to these nanoparticles. However, little is known about in vivo trafficking and 
deposition of Ag NPs. A few studies have reported very limited data on Ag NP accu-
mulation in organs, with relevant toxicological implications.8,9   Biocompatibility of 
Ag NPs may be a serious concern because several studies have shown that Ag NPs 
have cytotoxic and genotoxic effects on human cells.10,11 In addition, exposure to International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Dovepress
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Ag NPs is   associated with proinflammatory responses;12 
altered gene expression in brain tissues, indicating possible 
neurotoxicity;13 and even potential liver damage.9 Further-
more, Ag NPs induced developmental defects in zebrafish 
embryos.14,15 Despite the widespread application of Ag NPs 
and growing evidence of their potential toxicity, no studies 
have evaluated the primary targets and organ distribution 
pattern of Ag NPs following systemic administration. 
However, several studies have indicated the propensity of 
Ag NPs to translocate into circulation after pulmonary16–18 
and dermal exposure.19,20 Thus, there is an escalating need 
for the development of methods for direct imaging and 
tracking of Ag NPs in vivo.
Here, we have developed a technique for the rapid 
radiolabeling of Ag NPs with 125I-iodine. After systemic 
administration, the distribution pattern of  125I isotope-
tagged Ag NPs was traced in vivo by gamma-scintigraphic 
imaging, and tissue uptake was quantified by biodistribu-
tion analysis.
Experimental methods
Materials and animals
AgNO3 was purchased from Alfa Aesar (Ward Hill, MA). 
Iodobeads were obtained from Pierce (Rockford, IL). Pre-
packed Sephadex G-25 columns were acquired from GE 
Healthcare (Uppsala, Sweden). Carrier-free iodine-125 
was purchased from Perkin Elmer (Boston, MA). All other 
chemicals were obtained from Sigma-Aldrich (St Louis, 
MO). Nanopure water (.18.0 MΩcm-1) purified with the 
Millipore Milli-Q system was used in all the experiments.
All animal experiments were carried out in accordance 
with protocols approved by the Institutional Animal Care and 
Use Committee (IACUC). Animals were housed in the   animal 
care facility, and the animals that received radiolabeled nano-
particles were housed and imaged in a separate, lead-shielded 
animal facility. Balb/c mice (females, 25 g, 6–8 wks) were 
purchased from Jackson Laboratories (Sacramento, CA) and 
Fisher CDF rats (females, 125 g) were obtained from Charles 
River Laboratories (Wilmington, MA).
Synthesis of Ag NPs
Ag NPs were synthesized as described previously21 with 
minor modifications. Poly(N-vinyl-2-pyrrolidone, MW 
40,000) (PVP-40T) was used as a stabilizer and also as a 
weak reducing agent. In brief, 1 mM AgNO3 in the   presence 
of 1 mM PVP-40T, pH 8.8, was stirred at 60°C for 5 min. The 
reaction vessel was then cooled on ice for 20 min.   Thereafter, 
the nanoparticles were separated by   centrifugation at 20,000 g 
for 30 min (Beckman L8-M ultracentrifuge) at 4°C. The 
  pellet was then resuspended in 10 mM 4-(2-hydroxyethyl)
piperazine-1-ethanesulfonic acid (HEPES), pH 6.0, and 
centrifuged again to remove contaminants.
radiolabeling of Ag nanoparticles  
with iodine-125
Chloramine-T (N-chlorobenzenesulfonamide) immobilized 
on a polystyrene backbone (Iodobeads; Thermo Fisher, 
  Rockford, IL) was used as an oxidizer and incubated with 
1 mCi of   carrier-free Na 125I (Perkin Elmer) at room tempera-
ture for 10 min. The solution was then removed and added to a 
dispersion of unfunctionalized Ag nanoparticles (2.5 mg Ag) 
in 10 mM HEPES, pH 6.0, under rapid agitation with a vor-
tex. From this step forward, the samples were protected from 
light with aluminum foil. The mixture was then incubated at 
room temperature for 30 min on an orbital shaker (Labquake 
shaker; Labindustries,   Berkeley, CA) at 10 rpm. Unbound 
iodide-125 was removed by size exclusion chromatogra-
phy on Sephadex G-25 columns (GE Healthcare); 10 mM 
HEPES, pH 6.0, was used as an elution buffer. More than 
95% of Ag NPs was recovered after elution as determined 
from spectral measurements A (410 nm).
Characterization of nanoparticles
Nanoparticle formulations were analyzed for size   distribution 
by transmission electron microscopy (TEM) and photon 
correlation spectroscopy by using an N5 Submicron Particle 
Size Analyzer (Beckman Coulter, Miami, FL). For TEM, 
samples were dried on formvar-coated copper grids (Ted Pella, 
  Redding, CA) and analyzed using a Morgagni 268 D electron 
microscope equipped with a MegaView III digital camera. 
The ultraviolet-visible absorption spectra were recorded using 
a DU 640 spectrophotometer (Beckman Coulter,   Fullerton, 
CA). Dark-field images were acquired using a real-time 
microscope (RTM)-3 optical setup equipped with Richardson 
contrast (Richardson Technologies, Toronto, Canada).
In vivo biodistribution and computed 
tomography coregistered with single-
photon emission computerized 
tomography imaging
Balb/c mice were intravenously injected with 4 µCi of the 125I-Ag 
NP dispersion. Mice were anesthetized by   intraperitoneal 
injection of a mixture of ketamine (50 mg/kg) and xylazine 
(10 mg/kg), and computed   tomography   coregistered with International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
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single-photon emission computerized tomography (CT-
SPECT) imaging was performed at different time points. 
CT-SPECT scans were acquired using an X-SPECT second 
generation MicroSPECT® imaging system (Gamma Medica, 
Inc., Northridge, CA). SPECT images were obtained in a 
360° orbit with 30-s sampling every 6° with low energy, 
high-resolution parallel hole collimators and the pulse-height 
analyzer window set over the 30 keV photopeak of iodine-125. 
Tomographic reconstruction was performed using a standard 
filtered back projection. Three-dimensional data sets after CT-
SPECT fusion were processed on the AMIRA System (TGS, 
Inc., San Diego, CA). For biodistribution analysis, mice were 
sacrificed and the lung, liver, spleen, heart, colon, stomach, 
esophagus, muscle, brain, kidney, and pancreas were excised, 
scanned, and analyzed in the planar mode for 5 min. Radio-
activity of preweighed tissue samples was measured using 
the CobraII Auto-Gamma counter (Packard, Meriden, CT). 
Uptake values were corrected for radiodecay and expressed as 
a   percentage of the injected dose per gram of tissue (%ID/g). 
Fisher CDF rats were intravenously injected with 20 µCi of 
125I-Ag NPs and CT-SPECT images were acquired at the 
indicated time points.
Results
Synthesis, characterization,  
and radiolabeling of Ag NPs
Ag NPs were synthesized by reduction of silver nitrate 
using PVP as a polymer capping agent (see Exp. Methods). 
A colloidal dispersion of Ag NPs was radiolabeled by 
chemisorption of elemental iodine onto the metal surface. 
Free radioisotope was removed from the radiolabeled Ag NPs 
by size exclusion chromatography. The content of the free 
iodine in the sample was less than 0.5%, as estimated by 
analysis of the activity of the supernatant after centrifugation. 
The yield of radiolabeling was above 80%, with a specific 
activity of 0.4–0.6 µCi/µg of 125I-Ag NPs. Size analysis of 
radiolabeled nanoparticles by photon correlation spectros-
copy (PCS) revealed a relatively narrow size distribution; the 
sizes of 85% of the particles were within the range 9–16 nm, 
with an average size of 12 nm (Figure 1A). TEM confirmed 
this size distribution pattern (Figure 1B). TEM revealed that 
the particles were spherical; further, it provided the actual 
size of the electron-dense metallic part of the nanoparticles. 
PCS analysis, on the other hand, provided the hydrodynamic 
radius of PVP-capped  125I-Ag NPs. Radiolabeled Ag NPs 
exhibited light-scattering under dark field microscopy 
(Figure 1C) and showed strong surface plasmon resonance 
in the visible spectrum, ie, λmax = 410 nm (Figure 1D). The 
characteristic plasmon band of Ag NPs was unaltered after 
chemisorption of iodine-125 to the surface of Ag NPs.
In vivo imaging and biodistribution 
analysis of 125I-Ag NPs
In order to evaluate the tissue distribution pattern of Ag NPs 
in vivo, radiolabeled Ag NPs were intravenously injected as a 
bolus dose. Then gamma-scintigraphic images were acquired, 
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Figure 1 Characterization of synthesized silver nanoparticles (Ag NPs). A) Size distribution profile of  125I-Ag NPs as analyzed by photon correlation spectroscopy. 
B) Transmission electron microscopy (TeM) of 125I-Ag NPs. C) Light scattering as observed under a dark field real-time microscope (RTM). D) Absorption spectroscopy 
comparing Ag NPs and 125I-Ag NPs showed that the characteristic plasmon band for Ag NPs was not significantly altered after radiolabeling.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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and tissue uptake was analyzed 24 h later. We used SPECT 
imaging to analyze the spatial pattern of in vivo trafficking 
at the whole-body level. Acquisition of coregistered CT and 
SPECT images enabled us to correlate functional SPECT 
images of the spatial distribution of the 125I-Ag NPs with the 
anatomical information acquired by CT. CT-SPECT imaging 
revealed a strong 125I-Ag NP signal in the abdominal area, 
particularly, in the liver and spleen (Figure 2). The distribution 
of 125I-Ag NPs in the tissues was analyzed by planar gamma-
scintigraphic imaging of dissected organs, and the distribution 
was further quantified by measurement of radioactivity. Planar 
imaging of dissected tissue samples confirmed a strong 125I-Ag 
NP signal in the liver and spleen (Figure 3). Biodistribution 
analysis revealed that 125I-Ag NPs mainly accumulated in the 
liver (24.5%ID/g) and spleen (41.5%ID/g) (Table 1). Rela-
tively low uptakes were noted in the lungs and bone: 3.8%ID/g 
and 1.5%ID/g, respectively. Low levels of 125I-Ag NP in the 
blood (0.18%ID/g) were due to the clearance of 125I-Ag NPs 
from circulation by the reticuloendothelial system (RES). 
All other tissues (ie, tissues of the urinary bladder, stomach, 
kidney, esophagus, pancreas, skin, colon, heart, muscle, and 
brain) also showed a minimal uptake (,1%ID/g).
Additionally, to show that RES uptake of 125I-AgNPs is 
not species limited, we performed CT-SPECT imaging in 
rats (Figure 4). Imaging at different time points (0 min, 4 h, 
and 24 h) after intravenous administration confirmed sig-
nificant uptake by the liver. Thyroid uptake was negligible 
at 30 min and 4 h after injection, but it became apparent at 
24 h, indicating that the radiolabeled nanoparticles were 
catabolically dehalogenated.
Discussion
Despite widespread application of Ag NPs in the biomedi-
cal field1,2,22 and in consumer products,4,6 there are limited 
in vivo data regarding the biodistribution, organ deposition, 
and potential toxicity of Ag NPs.8,9 Ag NPs have been used 
as carriers of lanthanide complexes for designing potential 
nanoscale magnetic resonance imaging (MRI) contrast 
agents,23 and the use of Ag NPs-caged silica particles has been 
explored for ultrasonographic and photoacoustic imaging 
of pancreatic cancer in isolated perfused organs.24 Surface-
enhanced Raman scattering (SERS)-active silver colloids 
were used as plasmonic nanoprobes for in vitro biosensing 
and imaging.25 Besides these bioimaging-related studies, to 
the best of our knowledge, no reports exist on in vivo imaging 
of Ag NPs at the whole-body level.
Studies on rodent models indicate organ toxicity of 
Ag NPs.9,13 There are several although limited reports on 
the tissue distribution of Ag NPs after pulmonary exposure 
via inhalation.16–18 These studies indicate that Ag NPs may 
translocate from the site of exposure and accumulate in 
secondary targets, including the liver, spleen, and brain, 
after pulmonary exposure; this translocation presumably 
occurs via blood circulation or by transport within neurons. 
However, it is not completely clear if the silver accumulation 
in these tissues was due to the translocation of particles or 
released ions since the methods used in these studies do not 
distinguish between Ag NPs and ions.
Clinical studies evaluating absorption and systemic 
availability of Ag NPs from a burn wound dressing revealed 
elevated serum silver levels after dermal exposure.19,20 
Figure 2 Whole-body computed tomography coregistered with single-photon emission computerized tomography (CT-SPeCT) imaging of 125I-Ag NPs localization in mouse 
24 h after injection. Panels A, B, and D show computed tomography (CT) scans and corresponding fused CT-SPeCT images. Panel A depicts coronal slices and panel B, sagittal 
slices. Panel D shows axial slices along the indicated area of the thoracic and abdominal cavity. Panel C shows a 3-D image after fusion of volumetric SPeCT texture with the 
CT isosurface. Positions of the organs with accumulated radioactivity are indicated: liver (L), spleen (S), and thyroid (T).International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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In one of these studies,19 increased liver enzyme levels were 
observed, indicating that liver injury had occurred during 
treatment. After the Ag NP-based wound dressings were 
removed, liver function returned to normal, thus linking 
Ag NPs to liver toxicity. However, this link between silver 
ions and liver toxicity should be carefully considered.
In general, after intravenous administration of nanopar-
ticulate systems, the nanoparticles are taken up by the RES 
(phagocytic system of the liver and spleen), leading to clear-
ance of the nanoparticles from the systemic circulation.26 This 
uptake is primarily attributed to resident macrophage popula-
tions in the tissues, resulting in an inflammatory response.27 
After systemic administration of nanoparticles, prominent 
uptake of nanoparticles of   different sizes and compositions 
was noted in the RES. For example, studies of gold nanopar-
ticles (1.4 nm and 18 nm, 24 h),28 99mTc-labeled latex particles 
of different sizes (61–660 nm, 2 h),29 and gold core and silica 
shell nanoparticles (120 nm, 2 h) reported superior uptake 
of these particles in the liver,30 and studies of   64Cu-labeled 
CdTe (12 nm, 2–6 min) quantum dot   nanoparticles31 and 
gold nanoparticles (10, 50, 100, and 250 nm; 24 h)32 showed 
predominant uptake of these nanoparticles in the liver and 
spleen. A recent study revealed that ultrafine Ag NPs (2 nm) 
capped with bovine serum albumin (BSA) accumulated in the 
liver, spleen, and heart.8 In vivo uptake of these nanoparticles, 
particularly in the heart, might be mediated by the albumin 
receptor gp60 (albondin), which is expressed on the vascular 
endothelium.33
It has been suggested that modification of the nanopar-
ticle surface with hydrophilic polymers such as polyethylene 
glycol (PEG) might delay recognition and uptake by the 
RES and influence the biodistribution profile and clearance 
kinetics. However, even PEGylated nanoparticles exhibit 
a high affinity for the RES.27,31 In the case of 13-nm PEG-
coated Au NPs, uptake was primarily noted in the liver and 
spleen and was associated with acute inflammation and 
apoptosis in the liver.27 Nevertheless, grafting of hydrophilic 
polymers may expand surface chemistry for retargeting of 
nanoparticles by attachment of specific probes (antibodies, 
aptamers, peptides, etc.).
By using biodistribution analysis and CT-SPECT imag-
ing, we studied the tissue uptake of 125I-labeled Ag NPs after 
systemic administration (100% bioavailability) in mice. 
Noninvasive CT-SPECT has been previously used for small 
animal imaging to analyze tissue-specific accumulation of 
125I-labeled probes.34,35 The biodistribution data (Table 1) 
and in vivo CT-SPECT imaging (Figure 2) revealed that 
the uptake of Ag NPs was highest in the liver and spleen. 
The radioactivity in these tissues was due to the uptake of 
125I-Ag NPs and not free iodine-125. Free iodine is taken up 
rapidly by the thyroid gland, salivary gland, and stomach.36 
We observed minor thyroid uptake at 24 h in mice, probably 
because of catabolism of  125I-Ag NPs and release of free 
iodine. Low levels of uptake in the lung might be   attributable 
to the phagocytic activity of pulmonary macrophages. 
Furthermore, confirmatory extensive RES uptake was also 
observed at all analyzed time points in rats. High uptake of 
Ag NPs in the RES, particularly, in the liver, observed in 
our study implicates Ag-NPs-associated toxicity towards 
hepatic tissue. In fact, Ag NPs are highly toxic to rat liver 
cells in vitro,37 and chronic exposure (oral administration) 
Figure  3  Biodistribution  of  125I-Ag  NPs  in  mouse  24  h  after  intravenous 
administration  (4  µCi;  0.4  µCi/µg).  A)  Photograph  of  dissected  tissues.  B)  3D 
isosurface  reconstruction  of  CT  data.  C  and  D)  CT-SPeCT  fusion  of  dissected 
tissues. Tissues: 1, lung; 2, liver; 3, spleen; 4, heart; 5, colon; 6, stomach; 7, esophagus; 
8, muscle; 9, brain; 10, kidney; 11, pancreas.
Figure 4 CT-SPeCT images of iodine-125 labeled silver nanoparticles in rats at 
different  time  points  after  intravenous  administration.  Sagittal  slices  are  shown. 
Injected dosage: 20 µCi at a specific activity 0.6 µCi/µg. Positions of the liver (L) 
and thyroid (T) are indicated.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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of rats to Ag NPs can lead to liver damage.9 Liver injury has 
also been observed after dermal exposure during treatment 
with Ag NP-based wound dressings.19 These reports along 
with our results indicate that Ag NPs have high propensity 
for the liver, leading to hepatotoxic consequences.
Liver-specific accumulation of Ag NPs though hypo-
thetically beneficial for the treatment of antibiotic-resistant 
bacterial liver infections that might otherwise require liver 
resection;38 however, the potential toxicity of Ag NPs must 
be taken into account before these nanoparticles are applied 
in a clinical setting.
In our study, we used the 125I- isotope of iodine for radio-
labeling. This isotope is used mainly for in vitro assays, and 
it has recently been used in vivo for small animal imaging. 
Other radioisotopes of iodine, including 123I,  124I, and  131I, 
can similarly be used for radiolabeling of Ag NPs since they 
have the same chemical properties. Their specific emission 
properties have been exploited for radiotherapy (131I), SPECT 
  imaging (123I and  131I), and positron-emission tomographic 
imaging (124I). Therefore, radiolabeling using other iodine 
radioisotopes extends the radiotherapeutic and/or imaging 
potential of this technique. Since 131I and 125I isotopes have 
been used efficiently for tumor radiotherapy thus targeting or 
intracavitary brachytherapy seeding of 131I- or 131I-  radiolabeled 
Ag NPs may be potentially used as nanocarriers for irra-
diation, especially for the treatment of liver cancer. Various 
radiolabeled agents selectively   accumulate in the liver after 
intrahepatic arterial infusion, and these agents have been 
  clinically studied to determine their possible application in 
internal radiation   therapy of unresectable hepatocellular car-
cinoma. These include   90Y-microspheres,39   188Rh-conjugated 
lipiodol,40 and   131I-labeled lipiodol.41 Combining radiation 
doses delivered by 131I- or 125I-labeled Ag NPs with the reactive 
oxygen species cytotoxicity associated with Ag NPs could, in 
theory, provide a synergistic therapeutic outcome.
In conclusion, we have developed a rapid and simple 
method to radiolabel Ag NPs with the iodine-125 isotope. 
We have demonstrated the utility of this technique for in vivo 
Ag NP tracking by biodistribution analysis and SPECT imag-
ing. Our results showed prominent uptake of Ag NPs in the 
liver and spleen after intravenous administration. This finding 
implicates possible hepatotoxic consequences of Ag NPs and 
may warrant further toxicology study.
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